Finance

Lists
PTGX:NASDAQ
Protagonist Therapeutics Inc
$145.16
+0.05%
(+0.070) 1D
$146.51
+0.93% (+1.35)
Pre-market
Closed: Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTGX...
Open
$143.29
High
$146.51
Low
$142.00
Mkt. cap
9.39B
Avg. vol.
509.43K
Volume
617.00
P/E ratio
139.96
52-wk high
$160.81
52-wk low
$57.58
EPS
$1.04
Beta
1.80
Shares outstanding
64.71M
No. of employees
141
Open
$143.29
High
$146.51
Low
$142.00
Mkt. cap
9.39B
Avg. vol.
509.43K
Volume
617.00
P/E ratio
139.96
52-wk high
$160.81
52-wk low
$57.58
EPS
$1.04
Beta
1.80
Shares outstanding
64.71M
No. of employees
141
News stories
From web sources and news partners
About Protagonist Therapeutics Inc
CEO-
Employees141
Founded2006
HeadquartersNewark, California, United States
SectorBiotechnology
Websiteprotagonist-inc.com
Analyst ratings
Based on 12 analysts giving stock ratings to PTGX in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PTGX in the last 3 months.
Highest
Current $145.16
$186.00 (+28.13%)
Average
$167.00 (+15.05%)
Lowest
$121.00 (-16.64%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
$182.00
+25.4%
09/09/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$186.00
+28.1%
08/31/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$149.00
+2.6%
08/31/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
09/01/2026
Etzer Darout
Barclays
Buy
Maintained
$180.00
+24%
08/31/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$173.00
+19.2%
08/31/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$170.00
+17.1%
08/31/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$170.00
+17.1%
09/01/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$178.00
+22.6%
08/30/2026
Yun Zhong
Wedbush
Buy
Maintained
$173.00
+19.2%
08/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$155.00
+6.8%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
$121.00
-16.6%
07/16/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$110.00
-24.2%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.71M
7.44M
56.37M
213.48M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40.00M
46.36M
46.74M
42.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.13M
11.43M
13.28M
12.65M
Operating expense
51.13M
57.79M
60.02M
54.71M
Total operating expenses
51.13M
57.79M
60.02M
54.71M
Operating income
-46.42M
-50.36M
-3.65M
158.77M
Other non operating income
-
27.00K
53.00K
-81.00K
EBT including unusual items
-39.34M
-43.72M
2.28M
165.11M
EBT excluding unusual items
-39.34M
-43.72M
2.28M
165.11M
Income tax expense
-
666.00K
-1.50M
2.26M
Effective tax rate
-
-1.52%
-65.85%
1.37%
Other operating expenses
-
-
-
-
Net income
-39.34M
-44.38M
3.78M
162.85M
Net profit margin
-834.87%
-596.80%
6.71%
76.28%
Earnings per share
-0.62
-0.69
0.05
2.29
Interest and investment income
7.05M
6.76M
5.88M
6.43M
Interest expense
-
-
-
-
Net interest expenses
7.05M
6.76M
5.88M
6.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.06M
-49.98M
-3.24M
159.16M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps